Browse by Medical Category
The results are now in: the Phase 2 clinical drug trial, sponsored by Transition Therapeutics, was a success!; As many of you know, our Down Syndrome Program at Massachusetts General Hospital was one of 3 sites in the country selected to participate in this landmark study. We are thankful to the 6 adults with Down syndrome, and their caregivers, who participated at our clinic. Here's a summary of the study, and what this might mean for your son or daughter with Down syndrome in the future.
The next step will be to test ELND005 in a Phase 3 clinical drug trial. Dr. Tony Cruz, Chairman and CEO of Transition Therapeutics, will be working with us to help design the next phase.
For more information on all of the research opportunities at our MassGeneral Hospital Down Syndrome Program, please visit www.massgeneral.org/downsyndromeresearch or call Mary Ellen McDonough, RN, our senior clinical research coordinator at 617-643-5571.
This is an important moment for the Down syndrome community, and we will be sure to keep you posted on future developments.
Dr. Brian Skotko
Back to Top